This week, IP specialists gathered in London for the INTA conference, whilst courts in London, Munich and China went to great lengths to ensure that FRAND remains a hot topic of discussion. Although in his judgment on 1 May Justice Meade criticised the “dysfunctional system” that makes the effective negotiation of a cross-licence agreements for SEPs difficult and costly, he also set an example by awarding a FRAND rate sum.

In contrast, the court presided over by Oliver Schön in Munich granted ZTE a preliminary injunction against Samsung in the same dispute, setting new procedural standards. A Chinese court also ruled in ZTE’s favour on 1 May.

The UPC, however, did not weigh in on the FRAND debate this week. Instead, it demonstrated its speed in revocation actions when it revoked the Chinese Academy of Military Medical Sciences’ remdesivir patent for treating COVID-related illnesses. And that was not the UPC’s only decision in the life sciences sector this week.

However, as well as the need to keep up to date with case law, there is much more that successful patent lawyers and attorneys need to know. To bridge this gap, JUVE Patent is offering a new solution: we are launching PaceMaker, our brand-new premium newsletter crafted for those at the forefront of European patent practice. From now on, PaceMaker will be sent every Wednesday exclusively to paying subscribers, while our familiar fortnightly round-up shifts to Fridays and remains available to all readers free of charge.

PaceMaker is your gateway to independently researched original reporting and exclusive analysis you will find nowhere else. Our editorial approach is deliberately selective: depth over volume, orientation over noise, and a sharp focus on the trends and dynamics that influence strategic and commercial decisions for leading patent professionals. Whether you are advising a diverse portfolio of clients or competing for the next high-stakes case, PaceMaker keeps you one step ahead of the market.